Compare Incyte Corporation (INCY) vs Liquidia Corporation Common Stock (LQDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Liquidia Corporation Common Stock — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.63B), while Liquidia Corporation Common Stock trades at $34.27 (market cap $3.04B). The key difference: Incyte Corporation is far larger — about 7.4× Liquidia Corporation Common Stock's market cap, and Incyte Corporation is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Liquidia Corporation Common Stock for 0 Days on average.
| INCY | LQDA | |
|---|---|---|
Market Cap | $22.63B | $3.04B |
Volume | 1,869,988 | 21,111,778 |
Sector | Health | Health |
52-Week High | $129.93 | $91.03 |
52-Week Low | $86.17 | $22.02 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.13B | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $108.62, down 2.46% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.84, robust profitability margins, and a significant earnings beat in Q2 2026. Recent news highlights FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in sales. Operating cash flow surged to $1.41B in 2025, supporting financial health.
The outlook is mixed: analyst consensus is bullish with a $133.14 price target, but near-term technical pressure and Q3 2026's expected EPS loss pose risks. Long-term growth depends on pipeline execution and diversification beyond JAKAFI, with competitive and regulatory challenges as key investor considerations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →
